Apellis stock: buy or sell?

APLS stock price: $36.87 -5.32% At close on February 21st, 2020

Updated on:
February 21st, 2020


Shares of Apellis plunged a spooky -5.32% and closed at $36.87. Friday was the fifth red session in a row, sliding in full a -13.08%.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.

Should I buy Apellis stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Apellis stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Apellis Pharmaceuticals stock a buy?

Financial institutions and banks publish stock ratings everyday. Unfortunately, we couldn't detect any rating for APLS stock for the last 30 days.

Apellis stock analysis

Daily outlook

Shares of Apellis plunged a spooky -5.32% and closed at $36.87.

Shares of Apellis Pharmaceuticals ended today at $36.87 and plunged a spooky -5.32%. On December APLS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last December when SMA50d and SMA100d crossed up, APLS price gained $9.60 per share (35.20%). On Feb/10, APLS hit new all time highs, pushing higher previous ATH of $44.47 recorded on Feb 4th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

APLS stock chart (daily)

Weekly outlook

Shares of Apellis closed this week at $36.87 and collapsed a chilling -12.17%. By mid January APLS boosted a cool 5.11% in just one week.

Apellis stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, APLS might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last all-time high Apellis marked last week, but since then it dropped a 18.14%. Since price and SMA40w lines crossed up early December, APLS climbed $12.88 (53.69%). Since SMA20d and SMA40w crossed up early May, APLS price climbed $17.29 per share (88.30%).

APLS stock chart (weekly)

Apellis stock price history

Apellis IPO was on November 9th, 2017 at $14.50 per share1. Since then, APLS stock grew a 154.30%, with an average of 77.20% per year. If you had invested $1,000 in Apellis stock in 2017, it would worth $1,543.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Apellis stock historical price chart

APLS stock reached all-time highs on February 10th with a price of $45.04.

Apellis stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' APLS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price prediction for Apellis Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Apellis Pharmaceuticals let down analysts when it reported an Earnings per Share (EPS) of $-0.61 when the market consensus was $-0.65.
APLS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2011, last anual turnover report draw a fatal slide of -4.35% to $1,246.02 million dollars. When comparing 2012 vs 2011, however, profit margin (that is, the net income divided by revenues) plummed a -17.22% to 4.98%.

APLS annual Sales and Income evolution
2010$936 M-$270 M28.8%-
2011$1,303 M39.24%$289 M22.2%7.28%
2012$1,246 M-4.35%$62 M5.0%-78.54%

Quarterly financial results

Reported quarter income marked $-36.46 M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Apellis sales marked a neutral movement and stayed constant a nan%. Looking back to recent quarterly results, Apellis Pharmaceuticals posted 7 positive quarters in a row.
APLS quarterly Sales and Income evolution

Apellis ownership

When you are planning to buy a stock, it's worth to check its ownership structure.

Apellis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 22.31% of all shares.

In case of Apellis stock, 60.52% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for APLS stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

Market cap$2.8 B
Total shares74.9 M
Float shares46.7 M
  - Institutional holdings (%)60.5%
  - Insider holdings (%)22.3%
Shares in short selling0.0%

Apellis summary

Friday, February 21st, 2020
Day range$36.72 - $39.10
Previous close$38.94
Session gain-5.32%
Average true range$1.91
50d mov avg$36.83
100d mov avg$32.08
200d mov avg$28.61
Daily patternlt06c
Weekly pattern lt06a

Apellis performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Apellis Pharmaceuticals, the benchmark is made against .
APLSApellis Pharmaceu...37.47%30.14%159.28%

Apellis competitors

Unfortunately, we could not find any public company that could be defined as Apellis Pharmaceuticals competitor. This doesn't mean Apellis Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.